Zentek Ltd. announced the completion of the first phase of its Innovative Solutions Canada Testing Stream contract. This phase involved delivering a lead candidate countermeasure for highly pathogenic avian influenza (HPAI) A(H5N1).
The company has now successfully moved to the testing phase of the project, utilizing its Multivalent Aptamer Technology.
This milestone signifies important progress in Zentek's efforts to develop pharmaceutical products based on graphene compounds and aptamers for high-impact biomedical applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.